Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification

被引:2
|
作者
Feng, Lijuan [1 ]
Kan, Ying [1 ]
Wang, Wei [1 ]
Wang, Chao [2 ]
Zhang, Hui [3 ]
Xie, Peng [4 ]
Yang, Jigang [1 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Nucl Med, 95 Yong Rd, Beijing 100050, Peoples R China
[2] SinoUn Healthcare Inc, Beijing 100192, Peoples R China
[3] Tsinghua Univ, Sch Med, Dept Biomed Engn, Beijing 100084, Peoples R China
[4] Hebei Med Univ, Hosp 3, Dept Nucl Med, Shijiazhuang 050051, Peoples R China
关键词
Event-free survival; Neuroblastoma; Nomogram; Overall survival; Prognosis; MITOSIS-KARYORRHEXIS INDEX; CLASSIFICATION;
D O I
10.1007/s00432-023-05398-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeTo develop and validate a nomogram for predicting survival in intermediate- and high-risk neuroblastoma patients and to compare the accuracy of the nomogram in predicting survival with Children's Oncology Group (COG) risk stratification.MethodsA total of 885 intermediate- and high-risk neuroblastoma patients were enrolled in this study, including 243 patients from our hospital (the training set) and 642 patients from the TARGET database (the validation set). The factors related to event-free survival (EFS) and overall survival (OS) in neuroblastoma were determined to construct the nomogram by Cox regression analysis. The C-index, calibration curves, and area under the time-dependent receiver operating characteristic curves (AUCs) were used to assess the predictive performance of the nomogram.ResultsInternational Neuroblastoma Staging System stage and Mitosis-karyorrhexis index (MKI) were significant unfavorable factors for EFS, while MKI and MYCN status were significant unfavorable factors for OS. The C-index of the nomogram was 0.621 and 0.586 for predicting EFS, 0.650 and 0.570 for predicting OS in the training and validation sets, respectively. The calibration curves revealed good agreement in the EFS and OS predicted by the nomogram. The AUCs of the nomogram for 1-, 2-, 3-year EFS and OS were 0.633, 0.669, 0.604 and 0.672, 0.670, 0.702 in the training set, respectively. Moreover, the nomogram was able to classify patients into two groups according to risk scores, with the "high-risk" group having a lower survival rate than the "intermediate-risk" group. And the nomogram performed better than the COG risk stratification, which had a C-index of 0.537, 0.502 and 0.565, 0.572 for predicting EFS, OS in the training and validation sets, respectively.ConclusionWe developed and validated a prognostic nomogram for intermediate- and high-risk neuroblastoma patients that clinicians can use to make more informed decisions for individual patients.
引用
收藏
页码:16377 / 16390
页数:14
相关论文
共 50 条
  • [1] Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification
    Lijuan Feng
    Ying Kan
    Wei Wang
    Chao Wang
    Hui Zhang
    Peng Xie
    Jigang Yang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 16377 - 16390
  • [2] A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma
    Quan Sun
    Yanmin Chen
    Qianya Jin
    Xiaojun Yuan
    European Journal of Pediatrics, 2022, 181 : 4135 - 4147
  • [3] A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma
    Sun, Quan
    Chen, Yanmin
    Jin, Qianya
    Yuan, Xiaojun
    EUROPEAN JOURNAL OF PEDIATRICS, 2022, 181 (12) : 4135 - 4147
  • [4] Development and validation of a lung metastasis-predicting Nomogram for intermediate- to high-risk differentiated thyroid carcinoma patients
    Yu, Feng
    Ma, Wenhui
    Yang, Zhiping
    Yang, Weidong
    Wang, Jing
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [5] Development and validation of a lung metastases-predicting nomogram for intermediate- to high-risk differentiated thyroid carcinoma patients
    Ma, Wenhui
    Yu, Feng
    Chen, Bowen
    Yang, Zhiping
    Kang, Fei
    Li, Xiang
    Yang, Weidong
    Wang, Jing
    FUTURE ONCOLOGY, 2024, 20 (22) : 1575 - 1586
  • [6] Development and validation of a lung metastasispredicting Nomogram for intermediate- to high-risk differentiated thyroid carcinoma patients
    Yu, F.
    Wang, J.
    Yang, W.
    Yang, Z.
    Ma, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S667 - S667
  • [7] Risk Stratification and Management of Intermediate- and High-Risk Pulmonary Embolism
    Mojaddedi, Sanaullah
    Jamil, Javairia
    Bishev, Daniel
    Essilfie-Quaye, Kobina
    Elgendy, Islam Y.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (18)
  • [8] Study on the Survival Outcome of Intermediate-, and High-Risk Neuroblastoma from 2006 to 2015
    Zhang, Y.
    Zhang, W.
    Huang, D.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S287 - S287
  • [9] Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma: A Children's Oncology Group Report
    Umaretiya, Puja J.
    Naranjo, Arlene
    Zhang, Fan F.
    Park, Julie R.
    Weiss, Brian D.
    Granger, Meaghan
    Desai, Ami V.
    Ozkaynak, M. Fevzi
    Yu, Alice L.
    Aziz-Bose, Rahela
    Pruitt, Sandi L.
    Dubois, Steven G.
    Bagatell, Rochelle
    Bona, Kira
    JAMA NETWORK OPEN, 2025, 8 (02)
  • [10] Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma
    Bona, Kira
    Li, Yimei
    Winestone, Lena E.
    Getz, Kelly D.
    Huang, Yuan-Shung
    Fisher, Brian T.
    Desai, Ami, V
    Richardson, Troy
    Hall, Matt
    Naranjo, Arlene
    Henderson, Tara O.
    Aplenc, Richard
    Bagatell, Rochelle
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (03): : 282 - 291